Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Molecular Diagnosis & Therapy
Erschienen in: Molecular Diagnosis & Therapy 2/2017

01.04.2017 | Review Article

Epigenetic Biomarkers in Colorectal Cancer

verfasst von: Mukesh Verma, Vineet Kumar

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Developments in the diagnosis and treatment of colorectal cancer (CRC) have been made in the last decade, but the overall survival rate of patients with CRC has not improved dramatically. Genetic and epigenetic events contribute to CRC pathogenesis. Tumor heterogeneity results in a range of prognoses and responses to CRC management and therapy. Epigenetic biomarkers have potential in CRC diagnosis and in measuring response to therapy. Combining information from genetic and epigenetic alterations provides an opportunity to predict response to therapy. Epigenetic biomarkers can be used in disease stratification, which also helps in designing therapeutic approaches for CRC. Challenges in the understanding of CRC development and gaps in knowledge are discussed.
Literatur
1.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.PubMedCrossRef
2.
Nash GM, Gimbel M, Cohen AM, et al. KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol. 2010;17(2):416–24.PubMedCrossRef
3.
Aran V, Victorino AP, Thuler LC, Ferreira CG. Colorectal cancer: epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin Colorectal Cancer. 2016;15(3):195–203.PubMedCrossRef
4.
Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59(6):366–78.PubMedCrossRef
5.
Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev. 2010;19(8):1893–907.CrossRef
6.
Dolatkhah R, Somi MH, Kermani IA, Ghojazadeh M, Jafarabadi MA, Farassati F, Dastgiri S. Increased colorectal cancer incidence in Iran: a systematic review and meta-analysis. BMC Public Health. 2015;15:997.PubMedPubMedCentralCrossRef
7.
Bastani R, Glenn BA, Maxwell AE, et al. Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives. Cancer. 2015;121(17):2951–9.PubMedPubMedCentralCrossRef
8.
Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103(9):714–36.PubMedPubMedCentralCrossRef
9.
10.
11.
Lieberman D. Colon-polyp surveillance–do patients benefit? N Engl J Med. 2014;371(9):860–1.PubMedCrossRef
12.
Lieberman DA, American Gastroenterological Association. Colon polyp surveillance: clinical decision tool. Gastroenterology. 2014;146(1):305–6.PubMedCrossRef
13.
Lieberman DA, Weiss DG, Harford WV, et al. Five-year colon surveillance after screening colonoscopy. Gastroenterology. 2007;133(4):1077–85.PubMedCrossRef
14.
Rex DK, Lehman GA, Ulbright TM, et al. Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and family history. Am J Gastroenterol. 1993;88(6):825–31.PubMed
15.
Kahi CJ, Boland CR, Dominitz JA, et al. United states multi-society task force on colorectal, colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. Gastroenterology. 2016;150(3):758–768 e11.
16.
Klatsky AL, Li Y, Nicole Tran H, et al. Alcohol intake, beverage choice, and cancer: a cohort study in a large kaiser permanente population. Perm J. 2015;19(2):28–34.PubMedPubMedCentral
17.
Jacobs ET, Jurutka PW, Martinez ME, Alberts DS. Vitamin D, calcium, and colorectal neoplasia: new insights on mechanisms of action. Cancer Prev Res (Phila). 2009;2(3):197–9.PubMedPubMedCentralCrossRef
18.
Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology. 2015;148(6):1244–60 e16.
19.
Resler AJ, Makar KW, Heath L, et al. Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry. Carcinogenesis. 2014;35(9):2121–6.PubMedPubMedCentralCrossRef
20.
Alexander DD, Weed DL, Miller PE, Mohamed MA. Red meat and colorectal cancer: a quantitative update on the state of the epidemiologic science. J Am Coll Nutr. 2015;34(6):521–43.PubMedPubMedCentralCrossRef
21.
McCullough ML, Gapstur SM, Shah R, Jacobs EJ, Campbell PT. Association between red and processed meat intake and mortality among colorectal cancer survivors. J Clin Oncol. 2013;31(22):2773–82.PubMedPubMedCentralCrossRef
22.
Peppone LJ, Reid ME, Moysich KB, et al. The effect of secondhand smoke exposure on the association between active cigarette smoking and colorectal cancer. Cancer Causes Control. 2010;21(8):1247–55.PubMedPubMedCentralCrossRef
23.
Abdelfatah E, Kerner Z, Nanda N, Ahuja N. Epigenetic therapy in gastrointestinal cancer: the right combination. Therap Adv Gastroenterol. 2016;9(4):560–79.PubMedPubMedCentralCrossRef
24.
25.
Flint HJ, Duncan SH, Scott KP, Louis P. Links between diet, gut microbiota composition and gut metabolism. Proc Nutr Soc. 2015;74(1):13–22.PubMedCrossRef
26.
Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014;12(10):661–72.PubMedCrossRef
27.
Brennan CA, Garrett WS. Gut microbiota, inflammation, and colorectal cancer. Annu Rev Microbiol. 2016;70:395–411.PubMedCrossRef
28.
Tahara T, Yamamoto E, Suzuki H, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014;74(5):1311–8.PubMedPubMedCentralCrossRef
29.
Lamparella NE, Saroya BS, Yang Z, et al. Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine. Cancer Biol Ther. 2013;14(8):699–702.PubMedPubMedCentralCrossRef
30.
Zanutto S, Pizzamiglio S, Lampis A, et al. Methylation status in patients with early stage colon cancer: a new prognostic marker? Int J Cancer. 2012;130(2):488–9.PubMedCrossRef
31.
Coppede F, Migheli F, Lopomo A, et al. Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens: correlation with physiological and pathological characteristics, and with biomarkers of one-carbon metabolism. Epigenetics. 2014;9(4):621–33.PubMedPubMedCentralCrossRef
32.
Bae JM, Kim JH, Cho NY, Kim TY, Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer. 2013;109(4):1004–12.PubMedPubMedCentralCrossRef
33.
Dawson H, Koelzer VH, Lukesch AC, et al. Loss of Cdx2 expression in primary tumors and lymph node metastases is specific for mismatch repair-deficiency in colorectal cancer. Front Oncol. 2013;3:265.PubMedPubMedCentralCrossRef
34.
Sayar I, Akbas EM, Isik A, et al. Relationship among mismatch repair deficiency, CDX2 loss, p53 and E-cadherin in colon carcinoma and suitability of using a double panel of mismatch repair proteins by immunohistochemistry. Pol J Pathol. 2015;66(3):246–53.PubMedCrossRef
35.
36.
37.
38.
Baba Y, Ishimoto T, Kurashige J, et al. Epigenetic field cancerization in gastrointestinal cancers. Cancer Lett. 2016;375(2):360–6.PubMedCrossRef
39.
Markowitz O, Schwartz M, Feldman E, et al. Defining field cancerization of the skin using noninvasive optical coherence tomography imaging to detect and monitor actinic keratosis in ingenol mebutate 0.015%-treated patients. J Clin Aesthet Dermatol. 2016;9(5):18–25.
40.
Jakubek Y, Lang W, Vattathil S, et al. Genomic landscape established by allelic imbalance in the cancerization field of a normal appearing airway. Cancer Res. 2016;76(13):3676–83.PubMedCrossRef
41.
Asioli S, Morandi L, Cavatorta C, Cucchi MC, Foschini MP. The impact of field cancerization on the extent of duct carcinoma in situ (DCIS) in breast tissue after conservative excision. Eur J Surg Oncol. 2016;pii:S0748-7983(16)30672-2. doi:10.​1016/​j.​ejso.​2016.​07.​005.
42.
Verma M. The role of epigenomics in the study of cancer biomarkers and in the development of diagnostic tools. Adv Exp Med Biol. 2015;867:59–80.PubMedCrossRef
43.
Verma M. Genome-wide association studies and epigenome-wide association studies go together in cancer control. Future Oncol. 2016;12(13):1645–64.PubMedCrossRef
44.
Verma M, Khoury MJ, Ioannidis JP. Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling. Cancer Epidemiol Biomark Prev. 2013;22(2):189–200.CrossRef
45.
Verma M, Rogers S, Divi RL, et al. Epigenetic research in cancer epidemiology: trends, opportunities, and challenges. Cancer Epidemiol Biomark Prev. 2014;23(2):223–33.CrossRef
46.
Weisenberger DJ, Levine AJ, Long TI, et al. Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history. Cancer Epidemiol Biomark Prev. 2015;24(3):512–9.CrossRef
47.
Renaud F, Vincent A, Mariette C, et al. MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer. Int J Cancer. 2015;136(12):2811–21.PubMedCrossRef
48.
Jair KW, Bachman KE, Suzuki H, et al. De novo CpG island methylation in human cancer cells. Cancer Res. 2006;66(2):682–92.PubMedCrossRef
49.
Antelo M, Balaguer F, Shia J, et al. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One. 2012;7(9):e45357.PubMedPubMedCentralCrossRef
50.
51.
Ko M, An J, Rao A. DNA methylation and hydroxymethylation in hematologic differentiation and transformation. Curr Opin Cell Biol. 2015;37:91–101.PubMedPubMedCentralCrossRef
52.
Jin B, Yao B, Li JL, et al. DNMT1 and DNMT3B modulate distinct polycomb-mediated histone modifications in colon cancer. Cancer Res. 2009;69(18):7412–21.PubMedPubMedCentralCrossRef
53.
Zhang L, Zeng J, Zeng Z, et al. MGMT in colorectal cancer: a promising component of personalized treatment. Tumour Biol. 2016;37(8):11443–56.PubMedCrossRef
54.
Mohammad HP, Cai Y, McGarvey KM, et al. Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. Cancer Res. 2009;69(15):6322–30.PubMedPubMedCentralCrossRef
55.
Siggens L, Ekwall K. Epigenetics, chromatin and genome organization: recent advances from the ENCODE project. J Intern Med. 2014;276(3):201–14.PubMedCrossRef
56.
Verma M. Epigenome-Wide Association Studies (EWAS) in Cancer. Curr Genom. 2012;13(4):308–13.CrossRef
57.
Li L, Yang XJ. Molecular and functional characterization of histone deacetylase 4 (HDAC4). Methods Mol Biol. 2016;1436:31–45.PubMedCrossRef
58.
De Souza C, Chatterji BP. HDAC inhibitors as novel anti-cancer therapeutics. Recent Pat Anticancer Drug Discov. 2015;10(2):145–62.PubMedCrossRef
59.
de la Paz Sanchez M, Aceves-Garcia P, Petrone E. The impact of polycomb group (PcG) and trithorax group (TrxG) epigenetic factors in plant plasticity. New Phytol. 2015;208(3):684–94.CrossRef
60.
Geisler SJ, Paro R. Trithorax and polycomb group-dependent regulation: a tale of opposing activities. Development. 2015;142(17):2876–87.PubMedCrossRef
61.
Ma RG, Zhang Y, Sun TT, Cheng B. Epigenetic regulation by polycomb group complexes: focus on roles of CBX proteins. J Zhejiang Univ Sci B. 2014;15(5):412–28.PubMedPubMedCentralCrossRef
62.
Ahlquist T, Lind GE, Costa VL, et al. Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer. 2008;2008(7):94.CrossRef
63.
Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci. 1999;96(15):8681–6.
64.
Overman MJ, Morris V, Moinova H, et al. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016. doi:10.​18632/​oncotarget.​11317.
65.
Hoffmann AC, Vallbohmer D, Prenzel K, et al. Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J Cancer Res Clin Oncol. 2009;135(9):1231–7.PubMedCrossRef
66.
Lee BB, Lee EJ, Jung EH, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res. 2009;15(19):6185–91.PubMedCrossRef
67.
Lambert R, Tanaka S. Laterally spreading tumors in the colon and rectum. Eur J Gastroenterol Hepatol. 2012;24(10):1123–34.PubMedCrossRef
68.
Yagi K, Akagi K, Hayashi H, et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res. 2010;16(1);21–33.
69.
Sakai E, Ohata K, Chiba H, et al. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors. Int J Cancer. 2014;135(7):1586–95.PubMedCrossRef
70.
Salehi R, Atapour N, Vatandoust N, et al. Methylation pattern of ALX4 gene promoter as a potential biomarker for blood-based early detection of colorectal cancer. Adv Biomed Res. 2015;2015(4):252.CrossRef
71.
Gezer U, Yoruker EE, Keskin M, et al. Histone methylation marks on circulating nucleosomes as novel blood-based biomarker in colorectal cancer. Int J Mol Sci. 2015;16(12):29654–62.PubMedPubMedCentralCrossRef
72.
Benard A, Goossens-Beumer IJ, van Hoesel AQ, et al. Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early-stage colon cancer. BMC Cancer. 2014;2014(14):531.CrossRef
73.
Deb M, Sengupta D, Rath SK, et al. Clusterin gene is predominantly regulated by histone modifications in human colon cancer and ectopic expression of the nuclear isoform induces cell death. Biochim Biophys Acta. 2015;1852(8):1630–45.PubMedCrossRef
74.
75.
76.
77.
Yan L, Zhao W, Yu H, et al. A comprehensive meta-analysis of microRNAs for predicting colorectal cancer. Medicine (Baltimore). 2016;95(9):e2738.CrossRef
78.
Wang C, Zhao K, Rong Q. Diagnostic value of fecal microRNAs for colorectal cancer: a meta-analysis. Clin Lab. 2015;61(12):1845–53.PubMed
79.
Al-Sheikh YA, Ghneim HK, Softa KI, et al. Expression profiling of selected microRNA signatures in plasma and tissues of Saudi colorectal cancer patients by qPCR. Oncol Lett. 2016;11(2):1406–12.PubMed
80.
Sun Y, Liu Y, Cogdell D, et al. Examining plasma microRNA markers for colorectal cancer at different stages. Oncotarget. 2016;7(10):11434–49.PubMedPubMedCentral
81.
Sinicrope FA, Okamoto K, Kasi PM, Kawakami H. Molecular biomarkers in the personalized treatment of colorectal cancer. Clin Gastroenterol Hepatol. 2016;14(5):651–8.PubMedCrossRef
82.
Burki TK. Overtreatment of younger patients with colon cancer. Lancet Oncol. 2015;16(5):e203.PubMedCrossRef
83.
Kneuertz PJ, Chang GJ, Hu CY, et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 2015;150(5):402–9.PubMedCrossRef
84.
Smolle M, Uranitsch S, Gerger A, Pichler M, Haybaeck J. Current status of long non-coding RNAs in human cancer with specific focus on colorectal cancer. Int J Mol Sci. 2014;15(8):13993–4013.PubMedPubMedCentralCrossRef
85.
Xie X, Tang B, Xiao YF, et al. Long non-coding RNAs in colorectal cancer. Oncotarget. 2016;7(5):5226–39.PubMed
86.
Verma M, Maruvada P, Srivastava S. Epigenetics and cancer. Crit Rev Clin Lab Sci. 2004;41(5–6):585–607.PubMedCrossRef
87.
Verma M, Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol. 2002;3(12):755–63.PubMedCrossRef
88.
Chen H, Werner S, Butt J, et al. Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Oncotarget. 2016;7(13):16420–32.PubMedPubMedCentral
89.
Perrone F, Lampis A, Bertan C, et al. Circulating free DNA in a screening program for early colorectal cancer detection. Tumori. 2014;100(2):115–21.PubMed
90.
Huang MY, Tsai HL, Huang JJ, Wang JY. Clinical implications and future perspectives of circulating tumor cells and biomarkers in clinical outcomes of colorectal cancer. Transl Oncol. 2016;9(4):340–7.PubMedPubMedCentralCrossRef
91.
Bandaletova T, Chhaya V, Poullis A, Loktionov A. Colorectal mucus non-invasively collected from patients with inflammatory bowel disease and its suitability for diagnostic cytology. APMIS. 2016;124(3):160–8.PubMedCrossRef
92.
Shima K, Nosho K, Baba Y, et al. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: cohort study and literature review. Int J Cancer. 2011;128(5):1080–94.PubMedPubMedCentralCrossRef
93.
Dallol A, Al-Maghrabi J, Buhmeida A, et al. Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer. Cancer Epidemiol Biomark Prev. 2012;21(11):2069–75.CrossRef
94.
Zlobec I, Bihl M, Foerster A, et al. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol. 2011;225(3):336–43.PubMedCrossRef
95.
Zlobec I, Bihl MP, Foerster A, Rufle A, Lugli A. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology. 2012;61(5):777–87.PubMedCrossRef
96.
Network Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.CrossRef
97.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–67.PubMedCrossRef
98.
Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787–93.PubMedCrossRef
99.
Shiovitz S, Bertagnolli MM, Renfro LA, et al. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014;147(3):637–45.PubMedPubMedCentralCrossRef
100.
Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology. 2012;143(6):1442–1460 e1.
101.
Yan W, Guo M. Epigenetics of colorectal cancer. Methods Mol Biol. 2015;2015(1238):405–24.CrossRef
102.
Ronsch K, Jager M, Schopflin A. Class I and III HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 and EPHB tumor suppressor genes in colorectal cancer. Epigenetics. 2011;6(5):610–22.PubMedCrossRef
103.
Wei FZ, Cao Z, Wang X, et al. Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway. Autophagy. 2015;11(12):2309–22.PubMedCrossRef
104.
Noguchi T, Toiyama Y, Kitajima T, et al. miRNA-503 promotes tumor progression and is associated with early recurrence and poor prognosis in human colorectal cancer. Oncology. 2016;90(4):221–31.PubMedCrossRef
105.
Yang IP, Tsai HL, Huang CW, et al. High blood sugar levels significantly impact the prognosis of colorectal cancer patients through down-regulation of microRNA-16 by targeting Myb and VEGFR2. Oncotarget. 2016;7(14):18837–50.PubMedPubMedCentral
106.
Mokutani Y, Uemura M, Munakata K, et al. Down-regulation of microRNA-132 is associated with poor prognosis of colorectal cancer. Ann Surg Oncol. 2016;1–10. doi:10.​1245/​s10434-016-5133-3.
107.
Li Z, Wang H, Xu Z, Sun Y, Han J. Expression and mechanism of microRNA-181A on incidence and survival in late liver metastases of colorectal cancer. Oncol Rep. 2016;35(3):1403–8.PubMed
108.
Qin J, Ke J, Xu J, et al. Downregulation of microRNA-132 by DNA hypermethylation is associated with cell invasion in colorectal cancer. Onco Targets Ther. 2015;2015(8):3639–48.
109.
Basati G, Razavi AE, Pakzad I, Malayeri FA. Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer. Tumour Biol. 2016;37(2):1781–8.PubMedCrossRef
110.
Jia M, Gao X, Zhang Y, Hoffmeister M, Brenner H. Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin Epigenet. 2016;2016(8):25.CrossRef
111.
Nishihara R, Morikawa T, Kuchiba A, et al. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol. 2013;178(1):84–100.PubMedPubMedCentralCrossRef
112.
113.
Satia-Abouta J, Galanko JA, Martin CF, Ammerman A, Sandler RS. Food groups and colon cancer risk in African-Americans and Caucasians. Int J Cancer. 2004;109(5):728–36.PubMedCrossRef
114.
Grivennikov SI, Wang K, Mucida D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491(7423):254–8.PubMedPubMedCentral
115.
Vipperla K, O’Keefe SJ. Diet, microbiota, and dysbiosis: a ‘recipe’ for colorectal cancer. Food Funct. 2016;7(4):1731–40.PubMedCrossRef
116.
Mosen DM, Feldstein AC, Perrin NA, et al. More comprehensive discussion of CRC screening associated with higher screening. Am J Manag Care. 2013;19(4):265–71.PubMedPubMedCentral
117.
Javanparast S, Ward PR, Carter SM, Wilson CJ. Barriers to and facilitators of colorectal cancer screening in different population subgroups in Adelaide, South Australia. Med J Aust. 2012;196(8):521–3.PubMedCrossRef
118.
Mousavinezhad M, Majdzadeh R, Akbari Sari A, Delavari A, Mohtasham F. The effectiveness of FOBT vs. FIT: a meta-analysis on colorectal cancer screening test. Med J Islam Repub Iran. 2016;2016(30):366.
119.
Pickhardt PJ. Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: the importance of cancer prevention in addition to cancer detection. Abdom Radiol (NY). 2016;41(8):1441–4.
120.
Hirai K, Ishikawa Y, Fukuyoshi J, et al. Tailored message interventions versus typical messages for increasing participation in colorectal cancer screening among a non-adherent population: a randomized controlled trial. BMC Public Health. 2016;2016(16):431.CrossRef
121.
Robertson DJ, Lee JK, Boland CR, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology. 2016;pii:S0016-5085(16)35025-9. doi:10.​1053/​j.​gastro.​2016.​08.​053.
122.
Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160(3):171.PubMedPubMedCentralCrossRef
123.
Liang PS, Wheat CL, Abhat A, et al. Adherence to competing strategies for colorectal cancer screening over 3 years. Am J Gastroenterol. 2016;111(1):105–14.PubMedCrossRef
124.
Rousseau B, Chibaudel B, Bachet JB, et al. Stage II and stage III colon cancer: treatment advances and future directions. Cancer J. 2010;16(3):202–9.PubMedCrossRef
125.
Benard A, Zeestraten EC, Goossens-Beumer IJ, et al. DNA methylation of apoptosis genes in rectal cancer predicts patient survival and tumor recurrence. Apoptosis. 2014;19(11):1581–93.PubMedPubMedCentralCrossRef
126.
Zlobec I, Minoo P, Baker K, et al. Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. Eur J Cancer. 2007;43(6):1101–7.PubMedCrossRef
127.
Garziera M, Bidoli E, Cecchin E, et al. HLA-G 3′UTR polymorphisms impact the prognosis of stage II-III CRC patients in fluoropyrimidine-based treatment. PLoS One. 2015;10(12):e0144000.PubMedPubMedCentralCrossRef
128.
Patel SG, Lowery JT, Gatof D, Ahnen DJ. Practical opportunities to improve early detection and prevention of colorectal cancer (CRC) in members of high-risk families. Dig Dis Sci. 2015;60(3):748–61.PubMedCrossRef
129.
Schaeffer DF, Donnellan F. Endoscopic resection of malignant colonic polyps: why clinicopathological correlation (CPC) is needed for optimal treatment of CRC? Dig Dis Sci. 2015;60(9):2574–5.PubMedCrossRef
130.
Berretta M, Zanet E, Nasti G, et al. Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC). Arch Gerontol Geriatr. 2012;55(2):271–5.PubMedCrossRef
131.
132.
Vaish V, Khare T, Verma M, et al. Epigenetic therapy for colorectal cancer. Methods Mol Biol. 2015;2015(1238):771–82.CrossRef
133.
Gilsing AM, Weijenberg MP, Goldbohm RA, et al. The Netherlands Cohort Study-Meat Investigation Cohort; a population-based cohort over-represented with vegetarians, pescetarians and low meat consumers. Nutr J. 2013;2013(12):156.CrossRef
134.
Colditz GA, Manson JE, Hankinson SE. The Nurses’ Health Study: 20-year contribution to the understanding of health among women. J Womens Health. 1997;6(1):49–62.PubMedCrossRef
135.
Kenfield SA, DuPre N, Richman EL, et al. Mediterranean diet and prostate cancer risk and mortality in the Health Professionals Follow-up Study. Eur Urol. 2014;65(5):887–94.PubMedCrossRef
136.
Giles GG, English DR. The Melbourne Collaborative Cohort Study. IARC Sci Publ. 2002;2002(156):69–70.
137.
Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6B):1113–24.PubMedCrossRef
138.
Andriole GL, Reding D, Hayes RB, et al. The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: status and promise. Urol Oncol. 2004;22(4):358–61.PubMedCrossRef
139.
Samowitz WS, Albertsen H, Sweeney C, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst. 2006;98(23):1731–8.PubMedCrossRef
140.
Curtin K, Samowitz WS, Wolff RK, Herrick J, Caan BJ, Slattery ML. Somatic alterations, metabolizing genes and smoking in rectal cancer. Int J Cancer. 2009;125(1):158–64.PubMedPubMedCentralCrossRef
141.
Limsui D, Vierkant RA, Tillmans LS, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010;102(14):1012–22.PubMedPubMedCentralCrossRef
142.
Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013;26(4):465–84.PubMedPubMedCentralCrossRef
143.
Henderson D, Ogilvie LA, Hoyle N, et al. Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. Biotechnol J. 2014;9(9):1104–14.PubMedPubMedCentralCrossRef
144.
Nguyen MN, Choi TG, Nguyen DT, et al. CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer. Oncotarget. 2015;6(31):31674–92.PubMedPubMedCentral
145.
Hibi K, Mizukami H, Saito M, Kigawa G, Nemoto H, Sanada Y. FBN2 methylation is detected in the serum of colorectal cancer patients with hepatic metastasis. Anticancer Res. 2012;32(10):4371–4.PubMed
146.
Nilsson TK, Löf-Öhlin ZM, Sun XF. DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients. Int J Oncol. 2013;42(1):127–33.PubMed
147.
Moya P, Esteban S, Fernandez-Suarez A, et al. KiSS-1 methylation and protein expression patterns contribute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer. Tumour Biol. 2013;34(1):471–9.PubMedCrossRef
148.
Alonso S, González B, Ruiz-Larroya T, et al. Epigenetic inactivation of the extracellular matrix metallopeptidase ADAMTS19 gene and the metastatic spread in colorectal cancer. Clin Epigenet. 2015;7(1):1.CrossRef
149.
Moon JW, Choi JH, Lee SK, et al. Promoter hypermethylation of membrane type 3 matrix metalloproteinase is associated with cell migration in colorectal adenocarcinoma. Cancer Genet. 2015;208(5):261–70.PubMedCrossRef
150.
Liu M, Peng Y, Wang X, et al. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer. BMC Cancer. 2010;2010(10):160.CrossRef
151.
Chen H, Xu Z. Hypermethylation-associated silencing of miR-125a and miR-125b: a potential marker in colorectal cancer. Dis Markers. 2015;2015:345080.PubMedPubMedCentralCrossRef
152.
Kalmar A, Peterfia B, Hollosi P, et al. DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1, PTGDR and SFRP1 in colorectal adenoma and cancer. BMC Cancer. 2015;2015(15):736.CrossRef
153.
Philipp AB, Nagel D, Stieber P, et al. Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer. BMC Cancer. 2014;2014(14):245.CrossRef
154.
Tham C, Chew M, Soong R, et al. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. Cancer. 2014;120(20):3131–41.PubMedCrossRef
155.
Zhang ZM, Wang Y, Huang R, et al. TFAP2E hypermethylation was associated with survival advantage in patients with colorectal cancer. J Cancer Res Clin Oncol. 2014;140(12):2119–27.PubMedCrossRef
156.
Goossens-Beumer IJ, Benard A, van Hoesel AQ, et al. Age-dependent clinical prognostic value of histone modifications in colorectal cancer. Transl Res. 2015;165(5):578–88.PubMedCrossRef
157.
Metadaten
Titel
Epigenetic Biomarkers in Colorectal Cancer
verfasst von
Mukesh Verma
Vineet Kumar
Publikationsdatum
01.04.2017
Verlag
Springer International Publishing
Erschienen in
Molecular Diagnosis & Therapy / Ausgabe 2/2017
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-016-0244-x

Weitere Artikel der Ausgabe 2/2017

Molecular Diagnosis & Therapy 2/2017 Zur Ausgabe

Adis Diagnostic Profile

Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer

Original Research Article

Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma

Original Research Article

Analysis of rs8067378 Polymorphism in the Risk of Uterine Cervical Cancer from a Polish Population and its Impact on Gasdermin B Expression

Original Research Article

High Resolution Melting Analysis is Very Useful to Identify Breast Cancer Type 1 Susceptibility Protein (BRCA1) c.4964_4982del19 (rs80359876) Founder Calabrian Pathogenic Variant on Peripheral Blood and Buccal Swab DNA

Original Research Article

Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer

Review Article

Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise